Medical Expenditure Panel Survey

Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs medical expenditure panel survey, 1997-2000. Ann Intern Med 2005 142 891-7. 

Law AW, Reed SD, Sundy JS, Schulman KA Direct costs of allergic rhinitis in the United States Estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 2003 l 11 296-300. (Ill)... 

Stagnitti MN MBPS Medical Expenditure Panel Survey. Statistical Brief 21 Trends in Outpatient Prescription Drag Utilization and Expenditures 1997—2000 available at http //www.meps.ahrq.gov/papers/ st21/stat21.htm Introduction accessed on August 20, 2003. 

Awareness of prescriber nonadherence to hypertension treatment guidelines dates back at least to the 1990s (see (Cabana et al. 1999)). As one example of the financial ramifications, consider a retrospective analysis of year-2006 Medical Expenditure Panel Survey data reporting substantial costs of inappropriate hypertension management. Using year-2006 US dollars, the author noted that the overall prevalence of hypertension was estimated at 19.7 %, with 36% of identified patients treated inappropriately. The per-person cost for inappropriate treatment was 234.60, and the total national cost was approximately 13 billion (Balu 2009). While human costs are harder to quantify, they are no doubt commensurately disturbing (Turner 2013). 

---